Skip to content
← All treatment topics

TREATMENT READING

Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

36 sections
  1. Treatment Option Overview for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)
  2. Localized Disease
  3. Surgical Cytoreduction for Metastases
  4. Systemic Therapy for Advanced and Metastatic Disease
  5. Fluorouracil dosing
  6. Treatment of Gastrinoma
  7. Treatment of Insulinoma
  8. Treatment of Glucagonoma
  9. Treatment of Miscellaneous Islet Cell Tumors
  10. VIPoma
  11. Somatostatinoma
  12. Other Pancreatic Neuroendocrine Tumors
  13. Treatment of Recurrent and Progressive Pancreatic Neuroendocrine Tumors
  14. Certain factors affect prognosis (chance of recovery) and treatment options.
  15. The plan for cancer treatment depends on where the NET is found in the pancreas and whether it has spread.
  16. Pancreatic NETs can recur (come back) after they have been treated.
  17. Treatment Option Overview
  18. Key Points
  19. There are different types of treatment for patients with pancreatic NETs.
  20. The following types of treatment are used:
  21. Surgery
  22. Chemotherapy
  23. Hormone therapy
  24. Hepatic arterial occlusion or chemoembolization
  25. Targeted therapy
  26. Supportive care
  27. New types of treatment are being tested in clinical trials.
  28. Treatment for pancreatic neuroendocrine tumors may cause side effects.
  29. Patients may want to think about taking part in a clinical trial.
  30. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  31. Follow-up tests may be needed.
  32. Treatment of Gastrinoma
  33. Treatment of Insulinoma
  34. Treatment of Glucagonoma
  35. Treatment of Other Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)
  36. Treatment of Recurrent or Progressive Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Health professional

Treatment Option Overview for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Health professional · Treatment Option Overview for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Localized Disease

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

If technically and medically feasible, primary management of endocrine tumors of the pancreas involves surgical resection with curative intent. Given the rare nature of these tumors, surgical approaches are based on case series and expert opinion rather than randomized controlled trials.[1] The surgical options listed below are based on retrospective series from single reporting centers.[2-4][Level of evidence C2]

Sources: 1 · 2 · 4 · Level of evidence C2

Adjuvant therapy has no proven benefit and is, therefore, investigational. There have been no well-controlled trials of adjuvant therapy after complete tumor resection.[5]

Sources: 5

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment Option Overview for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Surgical Cytoreduction for Metastases

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Surgery plays a role even in the setting of metastatic disease. The symptoms of metastatic functional pancreatic neuroendocrine tumors (NETs) may be ameliorated by the reduction of overall tumor burden through surgical debulking.

The liver is a common site of metastasis from pancreatic NETs. Because of the slow growth rate of many NETs, liver metastases are often resected when technically feasible. Resection of all grossly visible liver metastases can be associated with long-term survival and, in the case of symptomatic hormonally functional tumors, symptom relief.[6] Most symptoms from functional tumors respond to this form of surgical debulking. It is not known if the favorable survival rates are attributable to patient selection factors (e.g., underlying patient condition, extent of metastases, slow doubling time, and so forth).

Sources: 6

Alternative approaches to the management of liver metastases have been reported, including Gelfoam embolization or transarterial chemoembolization,[7] radioembolization with radioactive microspheres,[8-10] radiofrequency ablation, cryoablation, and percutaneous alcohol ablation. These alternative approaches have been reviewed.[11]

Sources: 7 · 8 · 10 · 11

Results from surgical resection series appear to be more favorable than with these techniques, and surgery is considered to be the standard approach to resectable liver metastases. However, there are no high-quality studies comparing the various approaches. A systematic review of evidence comparing liver resection versus other treatments for patients with resectable liver neuroendocrine metastases found no randomized trials, or even quasi-experimental, cohort, or case-control studies in which the patient population given the alternative therapies was similar enough to the surgery group to draw reliable conclusions.[12] The evidence for resection of all grossly visible liver metastases is derived solely from case series.[Level of evidence C2]

Sources: 12 · Level of evidence C2

In most cases, liver metastases are not completely resectable. Cytoreductive surgery, with or without radiofrequency ablation or cryoablation, has been used to palliate symptoms. A systematic review found no randomized or quasi-randomized trials comparing cytoreductive surgery to other palliative approaches such as chemotherapy or tumor product inhibitors.[13] The evidence for surgical cytoreduction of unresectable liver metastases is restricted to case series [Level of evidence C2], and interpretation of outcomes may be strongly affected by patient selection factors.

Sources: 13 · Level of evidence C2

Health professional · Treatment Option Overview for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Systemic Therapy for Advanced and Metastatic Disease

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Somatostatin analogues may be effective in reducing the symptoms of functional tumors.[14]

Sources: 14

Chemotherapy using drugs such as the following, either alone or in combination, has been shown to have antitumor effects, but evidence is weak or conflicting regarding the impact of chemotherapy on overall survival:[15-17]

Sources: 15 · 17

Streptozocin.

Doxorubicin.

Fluorouracil.

Chlorozotocin.

Dacarbazine.

Temozolomide.

A variety of systemic agents have shown biological or palliative activity, including:[5,18]

Sources: 5 · 18

Tyrosine kinase inhibitors (e.g., sunitinib).

Temozolomide.

Vascular endothelial growth factor pathway inhibitors.

Mammalian target of rapamycin inhibitors (e.g., everolimus).

Nearly all of the evidence of activity is derived from case series.[Level of evidence C3] However, there are ongoing placebo-controlled randomized trials of everolimus [19] and sunitinib [20] that have been reported in abstract form showing an increase in progression-free survival in each case.[Level of evidence B1]

Sources: Level of evidence C3 · 19 · 20 · Level of evidence B1

Favorable responses have been reported in patients with advanced progressive pancreatic NETs after treatment with several radiolabeled somatostatin analogues in which the analogues octreotide, octreotate, lanreotide, or edotreotide are stably attached to the radionuclides indium In 111, yttrium Y 90, or lutetium Lu 177.[21-23] The relative efficacy of these various compounds is unknown. Study designs have been limited to case series with tumor response, biochemical response, or symptom control as the measure of efficacy.[Level of evidence C3]

Sources: 21 · 23 · Level of evidence C3

As noted in each of the clinical situations, there is a paucity or absence of high-level evidence and a need for randomized controlled trials.[5]

Sources: 5

Health professional · Treatment Option Overview for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) / Systemic Therapy for Advanced and Metastatic Disease

Fluorouracil dosing

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[24,25] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[24-26] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[27-29] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[30] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[31]

Sources: 24 · 25 · 24 · 26 · 27 · 29 · 30 · 31

Health professional

Treatment of Gastrinoma

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

The approach to treatment often depends on the results of preoperative localization studies and findings at exploratory laparotomy. At exploration, 85% of these tumors are found in the gastrinoma triangle with 40% on the surface of the pancreas and 40% outside of the pancreas. Only 15% are found within the substance of the pancreas. Percutaneous transhepatic venous sampling may occasionally provide accurate localization of single sporadic gastrinomas. Resection (enucleation of individual tumors, if technically feasible), and even excision of liver metastases, is associated with long-term cure or disease control.[1]

Sources: 1

Treatment options:

Single lesion in the head of the pancreas:[2-5]

Sources: 2 · 5

Single lesion in the head of the pancreas:[2-5]

Enucleation.

Parietal cell vagotomy and cimetidine.

Total gastrectomy (rarely used with the introduction of current therapies).

Single or multiple lesions in the duodenum:[2-5]

Sources: 2 · 5

Single or multiple lesions in the duodenum:[2-5]

Pancreatoduodenectomy.

Single lesion in the body/tail of the pancreas:[2-5]

Sources: 2 · 5

Single lesion in the body/tail of the pancreas:[2-5]

Resection of body/tail.

Multiple lesions in the pancreas:[2-5]

Sources: 2 · 5

Multiple lesions in the pancreas:[2-5]

Resection of body/tail.

If residual disease is present, parietal cell vagotomy and cimetidine.

Total gastrectomy (rarely used with the introduction of current therapies).

No tumor found:

No tumor found:

Parietal cell vagotomy and cimetidine.

Total gastrectomy (rarely used with the introduction of current therapies).

Liver metastases:[6-13]

Sources: 6 · 13

Liver metastases:[6-13]

Liver resection where possible.

Radiofrequency ablation or cryosurgical ablation.

Chemoembolization of liver.

Metastatic disease or disease refractory to surgery and cimetidine:[14-23]

Sources: 14 · 23

Metastatic disease or disease refractory to surgery and cimetidine:[14-23]

Chemotherapy

Somatostatin analogue therapy.

Patients with hepatic-dominant disease and substantial symptoms caused by tumor bulk or hormone-release syndromes may benefit from procedures that reduce hepatic arterial blood flow to metastases (hepatic arterial occlusion with embolization or with chemoembolization). Such treatment may also be combined with systemic chemotherapy in selected patients. Treatment with proton pump inhibitors or H2 blocking agents may aid in control of peptic symptoms.

In the era of proton pump inhibitors and H2 blocking agents, the potentially lethal hyperacidity and hypersecretory states induced by excessive gastrin production can usually be controlled. In a series of 212 patients with Zollinger-Ellison syndrome (ZES), no patients died of causes related to acid hypersecretion. Only 2.3% of those patients had undergone total gastrectomy, and the study cohort had a long median follow-up period of 13.8 years. Although 32% of the patients died during the course of the study, only 50% of the 67 deaths were attributable to ZES-related causes. Those causes were mainly liver metastases with progressive anorexia and cachexia (67%) or secondary endocrine tumors consequent to multiple endocrine neoplasia type 1 syndrome. The development of bone or liver metastases (especially diffuse liver disease) or of ectopic Cushing syndrome during the study period predicted for decreased survival times.[24]

Sources: 24

Health professional

Treatment of Insulinoma

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Curative surgical excision, by open laparotomy or laparoscopy, is the treatment of choice when possible. The open surgical approach is used if the tumor is suspected to be malignant because en bloc lymphadenectomy is performed for malignant tumors without distant metastases. Intraoperative ultrasonography aids the localization of tumor extent and the relationship to other anatomical structures.[1]

Sources: 1

Treatment options:

Single, small lesion in the head or tail of the pancreas:[1-4]

Sources: 1 · 4

Single, small lesion in the head or tail of the pancreas:[1-4]

Enucleation, if feasible.

Large lesion in the head of the pancreas that is not amenable to enucleation:[1-4]

Sources: 1 · 4

Large lesion in the head of the pancreas that is not amenable to enucleation:[1-4]

Pancreaticoduodenectomy.

Single, large lesion in the body/tail:[1-4]

Sources: 1 · 4

Single, large lesion in the body/tail:[1-4]

Distal pancreatectomy.

Multiple lesions (may occur in 10% of patients, often in association with multiple endocrine neoplasia syndrome type 1):[1-4]

Sources: 1 · 4

Multiple lesions (may occur in 10% of patients, often in association with multiple endocrine neoplasia syndrome type 1):[1-4]

Distal pancreatectomy with enucleation of tumors in the head of the pancreas.

Metastatic lesions in lymph nodes or distant sites:[5-12]

Sources: 5 · 12

Metastatic lesions in lymph nodes or distant sites:[5-12]

Resect when possible.

Consider radiofrequency or cryosurgical ablation, if not resectable.

Unresectable:[13-22]

Sources: 13 · 22

Unresectable:[13-22]

Combination chemotherapy.

Pharmacological palliation: diazoxide 300 to 500 mg/day.

Somatostatin analogue therapy.

Patients with hepatic-dominant disease and substantial symptoms caused by tumor bulk or hormone-release syndromes may benefit from procedures that reduce hepatic arterial blood flow to metastases (hepatic arterial occlusion with embolization or with chemoembolization).[6,8-12] Such treatment may also be combined with systemic chemotherapy in selected patients.

Sources: 6 · 8 · 12

Health professional

Treatment of Glucagonoma

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

As with the other pancreatic neuroendocrine tumors, the mainstay of therapy is surgical resection, and extended survival is possible even when the disease is metastatic. Resection of metastases is also a consideration when feasible.[1]

Sources: 1

Treatment options:

Single, small lesion in the head or tail of the pancreas:[1-4]

Sources: 1 · 4

Single, small lesion in the head or tail of the pancreas:[1-4]

Enucleation, if feasible.

Large lesion in the head of the pancreas that is not amenable to enucleation:[1-4]

Sources: 1 · 4

Large lesion in the head of the pancreas that is not amenable to enucleation:[1-4]

Pancreaticoduodenectomy.

Single, large lesion in the body/tail:[1-4]

Sources: 1 · 4

Single, large lesion in the body/tail:[1-4]

Distal pancreatectomy.

Multiple lesions:[1-4]

Sources: 1 · 4

Multiple lesions:[1-4]

Enucleation, if feasible.

Resect body and tail otherwise.

Metastatic disease in lymph nodes or distant sites:[5-12]

Sources: 5 · 12

Metastatic disease in lymph nodes or distant sites:[5-12]

Resect when possible.

Consider radiofrequency or cryosurgical ablation, if not resectable.

Unresectable disease:[13-22]

Sources: 13 · 22

Unresectable disease:[13-22]

Combination chemotherapy.

Somatostatin analogue therapy. Necrotizing erythema of glucagonoma may be relieved in 24 hours with somatostatin analogue, with nearly complete disappearance within 1 week.

Patients with hepatic-dominant disease and substantial symptoms caused by tumor bulk or hormone-release syndromes may benefit from procedures that reduce hepatic arterial blood flow to metastases (hepatic arterial occlusion with embolization or with chemoembolization).[6,8-12] Such treatment may also be combined with systemic chemotherapy in selected patients.

Sources: 6 · 8 · 12

Health professional

Treatment of Miscellaneous Islet Cell Tumors

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Health professional · Treatment of Miscellaneous Islet Cell Tumors

VIPoma

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Immediate fluid resuscitation is often necessary to correct the electrolyte and fluid problems that occur as a result of the watery diarrhea, hypokalemia, and achlorhydria that patients experience. Somatostatin analogues are also used to ameliorate the large fluid and electrolyte losses. Once patients are stabilized, excision of the primary tumor and regional nodes is the first line of therapy for clinically localized disease. In the case of locally advanced or metastatic disease, where curative resection is not possible, debulking and removal of gross disease, including metastases, should be considered to alleviate the characteristic manifestations of vasoactive intestinal peptide overproduction.[1] For more information, see the Treatment Option Overview for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) section.

Sources: 1 · Treatment Option Overview for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Health professional · Treatment of Miscellaneous Islet Cell Tumors

Somatostatinoma

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Complete excision is the therapy of choice, if technically possible. However, metastases often preclude curative resection, and palliative debulking can be considered to relieve symptoms.[1] For more information, see the Treatment Option Overview for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) section.

Sources: 1 · Treatment Option Overview for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Health professional · Treatment of Miscellaneous Islet Cell Tumors

Other Pancreatic Neuroendocrine Tumors

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

For these very rare tumors, complete surgical excision is the only curative option when technically possible. Debulking or somatostatin analogues are used for palliation of symptoms if the tumor is functional. For more information, see the Treatment Option Overview for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) section.

Sources: Treatment Option Overview for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Health professional

Treatment of Recurrent and Progressive Pancreatic Neuroendocrine Tumors

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

There is no established therapy for pancreatic neuroendocrine tumors that recur or progress after previous therapy.[1] Deciding on further treatment depends on many factors, including:

Sources: 1

The specific cancer.

Previous treatment.

Site of recurrence.

Individual patient considerations.

Attempts at re-resection of local tumors that have recurred or re-resection of metastatic lesions may offer palliation, when technically feasible. Intra-arterial chemotherapy is a consideration for patients with liver metastases. Patients with hepatic-dominant disease and substantial symptoms caused by tumor bulk or hormone-release syndromes may benefit from continuous-infusion intra-arterial chemotherapy or procedures that reduce hepatic arterial blood flow to metastases (hepatic arterial occlusion with embolization or with chemoembolization).[2-7] Such treatment may also be combined with systemic chemotherapy. A variety of systemic agents have shown biological or palliative activity,[1,8] including:

Sources: 2 · 7 · 1 · 8

Somatostatin analogues.

Radiolabeled somatostatin analogues.[9-11]

Sources: 9 · 11

Tyrosine kinase inhibitors (e.g., sunitinib).

Temozolomide.

Vascular endothelial growth factor pathway inhibitors.

Mammalian target of rapamycin inhibitors (e.g., everolimus).

For patients · General Information About Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

Pancreatic NETs can often be cured. The prognosis and treatment options depend on the following:

Sources: cured · prognosis

The type of cancer cell.

Where the tumor is found in the pancreas.

Whether the tumor has spread to more than one place in the pancreas or to other parts of the body.

Whether the patient has MEN1 syndrome.

The patient's age and general health.

Whether the cancer has just been diagnosed or has recurred (come back).

Sources: diagnosed · recurred

For patients · Stages of Pancreatic Neuroendocrine Tumors

The plan for cancer treatment depends on where the NET is found in the pancreas and whether it has spread.

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

The process used to find out if cancer has spread within the pancreas or to other parts of the body is called staging. The results of the tests and procedures used to diagnose pancreatic neuroendocrine tumors (NETs) are also used to find out whether the cancer has spread. See the General Information section for a description of these tests and procedures.

Sources: cancer · pancreas · staging · diagnose · pancreatic neuroendocrine tumors · General Information

Although there is a standard staging system for pancreatic NETs, it is not used to plan treatment. Treatment of pancreatic NETs is based on the following:

Sources: staging system

Whether the cancer is found in one place in the pancreas.

Sources: pancreas

Whether the cancer is found in several places in the pancreas.

Whether the cancer has spread to lymph nodes near the pancreas or to other parts of the body such as the liver, lung, peritoneum, or bone.

Sources: lymph nodes · liver · lung · peritoneum

For patients · Stages of Pancreatic Neuroendocrine Tumors

Pancreatic NETs can recur (come back) after they have been treated.

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

The tumors may come back in the pancreas or in other parts of the body.

For patients

Treatment Option Overview

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

There are different types of treatment for patients with pancreatic NETs.

The following types of treatment are used:

The following types of treatment are used:

Surgery

Chemotherapy

Hormone therapy

Hepatic arterial occlusion or chemoembolization

Targeted therapy

Supportive care

New types of treatment are being tested in clinical trials.

Treatment for pancreatic neuroendocrine tumors may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up tests may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with pancreatic NETs.

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

Different types of treatments are available for patients with pancreatic neuroendocrine tumors (NETs). Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: pancreatic neuroendocrine tumors · standard · clinical trials · research study · cancer

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

An operation may be done to remove the tumor. One of the following types of surgery may be used:

Sources: tumor · surgery

Enucleation: Surgery to remove the tumor only. This may be done when cancer occurs in one place in the pancreas.

Sources: Enucleation · pancreas

Pancreatoduodenectomy: A surgical procedure in which the head of the pancreas, the gallbladder, nearby lymph nodes and part of the stomach, small intestine, and bile duct are removed. Enough of the pancreas is left to make digestive juices and insulin. The organs removed during this procedure depend on the patient's condition. This is also called the Whipple procedure.

Sources: Pancreatoduodenectomy · gallbladder · lymph nodes · stomach · small intestine · bile duct · digestive · insulin · organs · condition · Whipple procedure

Distal pancreatectomy: Surgery to remove the body and tail of the pancreas. The spleen may also be removed if cancer has spread to the spleen.

Sources: Distal pancreatectomy · spleen

Total gastrectomy: Surgery to remove the whole stomach.

Sources: gastrectomy

Parietal cell vagotomy: Surgery to cut the nerve that causes stomach cells to make acid.

Sources: Parietal cell vagotomy · nerve · cells · acid

Liver resection: Surgery to remove part or all of the liver.

Sources: Liver · resection

Radiofrequency ablation: The use of a special probe with tiny electrodes that kill cancer cells. Sometimes the probe is inserted directly through the skin and only local anesthesia is needed. In other cases, the probe is inserted through an incision in the abdomen. This is done in the hospital with general anesthesia.

Sources: Radiofrequency ablation · local anesthesia · incision · abdomen · general anesthesia

Cryosurgical ablation: A procedure in which tissue is frozen to destroy abnormal cells. This is usually done with a special instrument that contains liquid nitrogen or liquid carbon dioxide. The instrument may be used during surgery or laparoscopy or inserted through the skin. This procedure is also called cryoablation.

Sources: Cryosurgical · ablation · tissue · abnormal · carbon dioxide · laparoscopy · cryoablation

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is the use of more than one anticancer drug. The way the chemotherapy is given depends on the type of the cancer being treated.

Sources: Chemotherapy · drugs · injected · vein · systemic chemotherapy · cerebrospinal fluid · cavity · regional chemotherapy · Combination chemotherapy

For patients · Treatment Option Overview / The following types of treatment are used:

Hormone therapy

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

Hormone therapy is a cancer treatment that removes hormones or blocks their action and stops cancer cells from growing. Hormones are substances made by glands in the body and circulated in the bloodstream. Some hormones can cause certain cancers to grow. If tests show that the cancer cells have places where hormones can attach (receptors), drugs, surgery, or radiation therapy is used to reduce the production of hormones or block them from working.

Sources: Hormone therapy · hormones · glands · receptors · radiation therapy

For patients · Treatment Option Overview / The following types of treatment are used:

Hepatic arterial occlusion or chemoembolization

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

Hepatic arterial occlusion uses drugs, small particles, or other agents to block or reduce the flow of blood to the liver through the hepatic artery (the major blood vessel that carries blood to the liver). This is done to kill cancer cells growing in the liver. The tumor is prevented from getting the oxygen and nutrients it needs to grow. The liver continues to receive blood from the hepatic portal vein, which carries blood from the stomach and intestine.

Sources: Hepatic arterial occlusion · blood · hepatic artery · blood vessel · oxygen · nutrients · hepatic portal vein · intestine

Chemotherapy delivered during hepatic arterial occlusion is called chemoembolization. The anticancer drug is injected into the hepatic artery through a catheter (thin tube). The drug is mixed with the substance that blocks the artery and cuts off blood flow to the tumor. Most of the anticancer drug is trapped near the tumor and only a small amount of the drug reaches other parts of the body.

Sources: chemoembolization · catheter · artery

The blockage may be temporary or permanent, depending on the substance used to block the artery.

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. Certain types of targeted therapies are being studied in the treatment of pancreatic NETs.

Sources: Targeted therapy

For patients · Treatment Option Overview / The following types of treatment are used:

Supportive care

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

Supportive care is given to lessen the problems caused by the disease or its treatment. Supportive care for pancreatic NETs may include treatment for the following:

Sources: Supportive care

Stomach ulcers may be treated with drug therapy such as:

Sources: ulcers · therapy

Stomach ulcers may be treated with drug therapy such as:

Proton pump inhibitor drugs such as omeprazole, lansoprazole, or pantoprazole.

Sources: Proton pump inhibitor · omeprazole · lansoprazole

Histamine blocking drugs such as cimetidine, ranitidine, or famotidine.

Sources: cimetidine

Somatostatin-type drugs such as octreotide.

Sources: octreotide

Diarrhea may be treated with:

Sources: Diarrhea

Diarrhea may be treated with:

Intravenous (IV) fluids with electrolytes such as potassium or chloride.

Sources: Intravenous · fluids · electrolytes · potassium

Somatostatin-type drugs such as octreotide.

Low blood sugar may be treated by having small, frequent meals or with drug therapy to maintain a normal blood sugar level.

Sources: blood sugar · drug therapy

High blood sugar may be treated with drugs taken by mouth or insulin by injection.

Sources: High blood sugar · insulin · injection

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview

Treatment for pancreatic neuroendocrine tumors may cause side effects.

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Gastrinoma

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of gastrinoma may include supportive care and the following:

Sources: gastrinoma · supportive care

For symptoms caused by too much stomach acid, treatment may be a drug that decreases the amount of acid made by the stomach.

Sources: symptoms · stomach acid · drug

For a single tumor in the head of the pancreas:

Sources: tumor · pancreas

For a single tumor in the head of the pancreas:

Surgery to remove the tumor.

Sources: Surgery

Surgery to cut the nerve that causes stomach cells to make acid and treatment with a drug that decreases stomach acid.

Sources: nerve · cells

Surgery to remove the whole stomach (rare).

For a single tumor in the body or tail of the pancreas, treatment is usually surgery to remove the body or tail of the pancreas.

For several tumors in the pancreas, treatment is usually surgery to remove the body or tail of the pancreas. If tumor remains after surgery, treatment may include either:

For several tumors in the pancreas, treatment is usually surgery to remove the body or tail of the pancreas. If tumor remains after surgery, treatment may include either:

Surgery to cut the nerve that causes stomach cells to make acid and treatment with a drug that decreases stomach acid; or

Surgery to remove the whole stomach (rare).

For one or more tumors in the duodenum (the part of the small intestine that connects to the stomach), treatment is usually pancreatoduodenectomy (surgery to remove the head of the pancreas, the gallbladder, nearby lymph nodes and part of the stomach, small intestine, and bile duct).

Sources: duodenum · small intestine · pancreatoduodenectomy · gallbladder · lymph nodes · stomach · small intestine · bile duct

If no tumor is found, treatment may include the following:

If no tumor is found, treatment may include the following:

Surgery to cut the nerve that causes stomach cells to make acid and treatment with a drug that decreases stomach acid.

Surgery to remove the whole stomach (rare).

If the cancer has spread to the liver, treatment may include:

Sources: cancer · liver

If the cancer has spread to the liver, treatment may include:

Surgery to remove part or all of the liver.

Radiofrequency ablation or cryosurgical ablation.

Sources: Radiofrequency ablation · cryosurgical · ablation

Chemoembolization.

Sources: Chemoembolization

If cancer has spread to other parts of the body or does not get better with surgery or drugs to decrease stomach acid, treatment may include:

If cancer has spread to other parts of the body or does not get better with surgery or drugs to decrease stomach acid, treatment may include:

Chemotherapy.

Sources: Chemotherapy

Hormone therapy.

Sources: Hormone therapy

If the cancer mostly affects the liver and the patient has severe symptoms from hormones or from the size of tumor, treatment may include:

Sources: hormones

If the cancer mostly affects the liver and the patient has severe symptoms from hormones or from the size of tumor, treatment may include:

Hepatic arterial occlusion, with or without systemic chemotherapy.

Sources: Hepatic arterial occlusion · systemic chemotherapy

Chemoembolization, with or without systemic chemotherapy.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Insulinoma

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of insulinoma may include the following:

Sources: insulinoma

For one small tumor in the head or tail of the pancreas, treatment is usually surgery to remove the tumor.

Sources: tumor · pancreas · surgery

For one large tumor in the head of the pancreas that cannot be removed by surgery, treatment is usually pancreatoduodenectomy (surgery to remove the head of the pancreas, the gallbladder, nearby lymph nodes and part of the stomach, small intestine, and bile duct).

Sources: pancreatoduodenectomy · gallbladder · lymph nodes · stomach · small intestine · bile duct

For one large tumor in the body or tail of the pancreas, treatment is usually a distal pancreatectomy (surgery to remove the body and tail of the pancreas).

Sources: distal pancreatectomy

For more than one tumor in the pancreas, treatment is usually surgery to remove any tumors in the head of the pancreas and the body and tail of the pancreas.

For tumors that cannot be removed by surgery, treatment may include the following:

For tumors that cannot be removed by surgery, treatment may include the following:

Combination chemotherapy.

Sources: Combination chemotherapy

Palliative drug therapy to decrease the amount of insulin made by the pancreas.

Sources: Palliative · drug · therapy · insulin

Hormone therapy.

Sources: Hormone therapy

Radiofrequency ablation or cryosurgical ablation.

For cancer that has spread to lymph nodes or other parts of the body, treatment may include the following:

Sources: lymph nodes

For cancer that has spread to lymph nodes or other parts of the body, treatment may include the following:

Surgery to remove the cancer.

Radiofrequency ablation or cryosurgical ablation, if the cancer cannot be removed by surgery.

Sources: Radiofrequency ablation · cryosurgical · ablation

If the cancer mostly affects the liver and the patient has severe symptoms from hormones or from the size of tumor, treatment may include:

Sources: cancer · liver · symptoms · hormones

If the cancer mostly affects the liver and the patient has severe symptoms from hormones or from the size of tumor, treatment may include:

Hepatic arterial occlusion, with or without systemic chemotherapy.

Sources: Hepatic arterial occlusion · systemic chemotherapy

Chemoembolization, with or without systemic chemotherapy.

Sources: Chemoembolization

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Glucagonoma

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment may include the following:

For one small tumor in the head or tail of the pancreas, treatment is usually surgery to remove the tumor.

Sources: tumor · pancreas · surgery

For one large tumor in the head of the pancreas that cannot be removed by surgery, treatment is usually pancreatoduodenectomy (surgery to remove the head of the pancreas, the gallbladder, nearby lymph nodes and part of the stomach, small intestine, and bile duct).

Sources: pancreatoduodenectomy · gallbladder · lymph nodes · stomach · small intestine · bile duct

For more than one tumor in the pancreas, treatment is usually surgery to remove the tumor or surgery to remove the body and tail of the pancreas.

For tumors that cannot be removed by surgery, treatment may include the following:

For tumors that cannot be removed by surgery, treatment may include the following:

Combination chemotherapy.

Sources: Combination chemotherapy

Hormone therapy.

Sources: Hormone therapy

Radiofrequency ablation or cryosurgical ablation.

Sources: Radiofrequency ablation · cryosurgical

For cancer that has spread to lymph nodes or other parts of the body, treatment may include the following:

For cancer that has spread to lymph nodes or other parts of the body, treatment may include the following:

Surgery to remove the cancer.

Radiofrequency ablation or cryosurgical ablation, if the cancer cannot be removed by surgery.

Sources: ablation

If the cancer mostly affects the liver and the patient has severe symptoms from hormones or from the size of tumor, treatment may include:

Sources: cancer · liver · symptoms · hormones

If the cancer mostly affects the liver and the patient has severe symptoms from hormones or from the size of tumor, treatment may include:

Hepatic arterial occlusion, with or without systemic chemotherapy.

Sources: Hepatic arterial occlusion · systemic chemotherapy

Chemoembolization, with or without systemic chemotherapy.

Sources: Chemoembolization

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Other Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

For VIPoma, treatment may include the following:

Fluids and hormone therapy to replace fluids and electrolytes that have been lost from the body.

Sources: Fluids · hormone therapy · electrolytes

Surgery to remove the tumor and nearby lymph nodes.

Sources: Surgery · tumor · lymph nodes

Surgery to remove as much of the tumor as possible when the tumor cannot be completely removed or has spread to distant parts of the body. This is palliative therapy to relieve symptoms and improve the quality of life.

Sources: palliative therapy · symptoms · quality of life

For tumors that have spread to lymph nodes or other parts of the body, treatment may include the following:

For tumors that have spread to lymph nodes or other parts of the body, treatment may include the following:

Surgery to remove the tumor.

Radiofrequency ablation or cryosurgical ablation, if the tumor cannot be removed by surgery.

Sources: Radiofrequency ablation · cryosurgical · ablation

For tumors that continue to grow during treatment or have spread to other parts of the body, treatment may include the following:

For tumors that continue to grow during treatment or have spread to other parts of the body, treatment may include the following:

Chemotherapy.

Sources: Chemotherapy

Targeted therapy.

Sources: Targeted therapy

For somatostatinoma, treatment may include the following:

Surgery to remove the tumor.

For cancer that has spread to distant parts of the body, surgery to remove as much of the cancer as possible to relieve symptoms and improve quality of life.

For tumors that continue to grow during treatment or have spread to other parts of the body, treatment may include the following:

For tumors that continue to grow during treatment or have spread to other parts of the body, treatment may include the following:

Chemotherapy.

Targeted therapy.

Treatment of other types of pancreatic neuroendocrine tumors (NETs) may include the following:

Sources: pancreatic neuroendocrine tumors

Surgery to remove the tumor.

For cancer that has spread to distant parts of the body, surgery to remove as much of the cancer as possible or hormone therapy to relieve symptoms and improve quality of life.

For tumors that continue to grow during treatment or have spread to other parts of the body, treatment may include the following:

For tumors that continue to grow during treatment or have spread to other parts of the body, treatment may include the following:

Chemotherapy.

Targeted therapy.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Recurrent or Progressive Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 7, 2022. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of pancreatic neuroendocrine tumors (NETs) that continue to grow during treatment or recur (come back) may include the following:

Sources: pancreatic neuroendocrine tumors · recur

Surgery to remove the tumor.

Sources: Surgery · tumor

Chemotherapy.

Sources: Chemotherapy

Hormone therapy.

Sources: Hormone therapy

Targeted therapy.

Sources: Targeted therapy

For liver metastases:

Sources: liver metastases

For liver metastases:

Regional chemotherapy.

Sources: Regional chemotherapy

Hepatic arterial occlusion or chemoembolization, with or without systemic chemotherapy.

Sources: Hepatic arterial occlusion · chemoembolization · systemic chemotherapy

A clinical trial of a new therapy.

Sources: clinical trial · therapy

Studies

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

NCT02595424 · ACTIVE NOT RECRUITING · phase2

Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma

ClinicalTrials.gov record

Disease and treatment settings

localized Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Disease and treatment setting

Localized Disease

metastatic Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Disease and treatment setting

Systemic Therapy for Advanced and Metastatic Disease

Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Disease and treatment setting

Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Proglycem: Adenoma after prior therapy

Disease and treatment setting

INDICATIONS AND USAGE PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy.

recurrent Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Disease and treatment setting

Treatment of Recurrent and Progressive Pancreatic Neuroendocrine Tumors

Drug labels

Proglycem

Label date 2024-07-19

INDICATIONS AND USAGE PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants...

DailyMed label